Nirsevimab

Nirsevimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	F protein of RSV
Clinical data
Trade names	Beyfortus
Other names	MEDI8897; nirsevimab-alip;
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Nirsevimab;
Pregnancy; category	AU: B2;
Routes of; administration	Intramuscular
ATC code	J06BD08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1989556-22-0;
PubChem SID	384585358;
DrugBank	DB16258;
UNII	VRN8S9CW5V;
KEGG	D11380;
ChEMBL	ChEMBL4297575;
Chemical and physical data
Formula	C6494H10060N1708O2050S46
Molar mass	146336.58 g·mol−1

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.

The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given).

It was developed by AstraZeneca and Sanofi. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022, in Canada in April 2023, and in the United States in July 2023. Alternatively, in October 2023 the CDC recommended maternal RSVpreF vaccination during pregnancy, though both are not needed in most infants.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.